• About
  • Privacy Policy
  • Terms Of Use
  • Contact
Tuesday, January 31, 2023
Pharma Info Nepal
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice
No Result
View All Result
Pharma Info Nepal
No Result
View All Result
Home Notice

WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

Nabin Bista by Nabin Bista
October 7, 2021
in Notice, Updates
0
WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk
80
VIEWS
Share on FacebookShare on Twitter

WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

 

Historic RTS,S/AS01 recommendation can reinvigorate the fight against malaria

WHO (World Health Organization) is recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission. The recommendation is based on results from an ongoing pilot programme in Ghana, Kenya and Malawi that has reached more than 800 000 children since 2019.

“This is a historic moment. The long-awaited malaria vaccine for children is a breakthrough for science, child health and malaria control,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus. “Using this vaccine on top of existing  tools to prevent malaria could save tens of thousands of young lives each year.”

Malaria remains a primary cause of childhood illness and death in sub-Saharan Africa. More than 260 000 African children under the age of five die from malaria annually.

In recent years, WHO and its partners have been reporting a stagnation in progress against the deadly disease.

“For centuries, malaria has stalked sub-Saharan Africa, causing immense personal suffering,” said Dr Matshidiso Moeti, WHO Regional Director for Africa. “We have long hoped for an effective malaria vaccine and now for the first time ever, we have such a vaccine recommended for widespread use. Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease and we expect many more African children to be protected from malaria and grow into healthy adults.”

WHO recommendation for the RTS,S malaria vaccine

Based on the advice of two WHO global advisory bodies, one for immunization and the other for malaria, the Organization recommends that:

WHO recommends that in the context of comprehensive malaria control the RTS,S/AS01 malaria vaccine be used for the prevention of P. falciparum malaria in children living in regions with moderate to high transmission as defined by WHO.  RTS,S/AS01 malaria vaccine should be provided in a schedule of 4 doses in children from 5 months of age for the reduction of malaria disease and burden.

Summary of key findings of the malaria vaccine pilots

Key findings of the pilots informed the recommendation based on data and insights generated from two years of vaccination in child health clinics in the three pilot countries, implemented under the leadership of the Ministries of Health of Ghana, Kenya and Malawi. Findings include:

  • Feasible to deliver: Vaccine introduction is feasible, improves health and saves lives, with good and equitable coverage of RTS,S seen through routine immunization systems. This occurred even in the context of the COVID-19 pandemic.
  • Reaching the unreached: RTS,S increases equity in access to malaria prevention.
    • Data from the pilot programme showed that more than two-thirds of children in the 3 countries who are not sleeping under a bednet are benefitting from the RTS,S vaccine.
    • Layering the tools results in over 90% of children benefitting from at least one preventive intervention (insecticide treated bednets or the malaria vaccine).
  • Strong safety profile: To date, more than 2.3 million doses of the vaccine have been administered in 3 African countries – the vaccine has a favorable safety profile.
  • No negative impact on uptake of bednets, other childhood vaccinations, or health seeking behavior for febrile illness. In areas where the vaccine has been introduced, there has been no decrease in the use of insecticide-treated nets, uptake of other childhood vaccinations or health seeking behavior for febrile illness.
  • High impact in real-life childhood vaccination settings: Significant reduction (30%) in deadly severe malaria, even when introduced in areas where insecticide-treated nets are widely used and there is good access to diagnosis and treatment.
  • Highly cost-effective: Modelling estimates that the vaccine is cost effective in areas of moderate to high malaria transmission.

Next steps for the WHO-recommended malaria vaccine will include funding decisions from the global health community for broader rollout, and country decision-making on whether to adopt the vaccine as part of national malaria control strategies.

Financial support

Financing for the pilot programme has been mobilized through an unprecedented collaboration among three key global health funding bodies: Gavi, the Vaccine Alliance; the Global Fund to Fight AIDS, Tuberculosis and Malaria; and Unitaid.

Notes:

  • The malaria vaccine, RTS,S, acts against P. falciparum, the most deadly malaria parasite globally, and the most prevalent in Africa.
  • The Malaria Vaccine Implementation Programme is generating evidence and experience on the feasibility, impact and safety of the RTS,S malaria vaccine in real-life, routine settings in selected areas of Ghana, Kenya and Malawi.
  • Pilot malaria vaccine introductions are led by the Ministries of Health of Ghana, Kenya and Malawi.
  • The pilot programme will continue in the 3 pilot countries to understand the added value of the 4th vaccine dose, and to measure longer-term impact on child deaths.
  • The Malaria Vaccine Implementation Programme is coordinated by WHO and supported by in-country and international partners, including PATH, UNICEF and GSK, which is donating up to 10 million doses of the vaccine for the pilot.
  • The RTS,S malaria vaccine is the result of 30 years of research and development by GSK and through a partnership with PATH, with support from a network of African research centres.
  • The Bill & Melinda Gates Foundation provided catalytic funding for late-stage development of RTS,S between 2001 and 2015.

 

WHO Recommends Groundbreaking Malaria Vaccine for Children at Risk

 

Source: https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk

 



  • WHO Prioritizes Access to Diabetes and Cancer Treatments in new Essential Medicines Lists
  • WHO Model List of Essential Medicines 22nd List (2021)

 

Tags: Malaria VaccineWHO
Previous Post

WHO Prioritizes Access to Diabetes and Cancer Treatments in new Essential Medicines Lists

Next Post

Vacancy Announcement Quest Pharmaceuticals

Nabin Bista

Nabin Bista

Hello, Thank You for visiting my blog I am Nabin Bista, Dedicated and self motivated young Pharmacist from Nepal. Blogging is my passion. I am studying B Pharmacy at Institute of Medicine - IOM. If you want me to write about any posts that you found confusing/difficult, please mention in the comments below.

Related Posts

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

January 9, 2023
Nepal Pharmacy Counci Notice

Nepal Pharmacy Council Notice

January 5, 2023
Load More
Next Post
Vacancy Announcement Quest Pharmaceuticals

Vacancy Announcement Quest Pharmaceuticals

Discussion about this post

Recommended

Vacancy Announcement Dhanushadham Municipality

Vacancy Announcement Dhanushadham Municipality

2 years ago
In the pharmacy profession the distortion increased when owner of pharmacy and pharmacists became different in Nepal

Pharmacy Profession the Distortion Increased in Nepal

2 years ago

Don't Miss

FDA-Approved HIV Medicines

FDA Approved HIV Medicines

January 26, 2023
Combined Oral Contraceptives (COC)

Combined Oral Contraceptives (COC)

January 17, 2023
Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

Nepal Pharmacy Council 21st Name Registration Exam Application Form Notice

January 9, 2023
Nepal Pharmacy Counci Notice

Nepal Pharmacy Council Notice

January 5, 2023

About Pharma Info Nepal

Pharma Info Nepal (Nabin’s Blog) was initiated in 2019 with the aim of providing relevant and accurate information for pharmacy, nursing and other health professionals. Since then it is conveying health related educational and informational updates of Nepal. It serves as a source for learning materials on diverse topics relating to medicine intended basically for pharmacy and nursing students. It covers job opportunities, question collections for pharmacy license, nursing license as well as various competitive exams.

Our readers rely on us for the well referenced and latest updates collected from the reliable sites.

Follow us

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Instagram

Information Reader

Contents (text, image, graphics, documents and other materials) published on this portal are collected from other relevant sources with the sole purpose of sharing information. Contents and features are subject to change and all rights reserved to Pharma info Nepal. The information presented on this web portal and its official social media handles have no affiliation to any organization that author is involved with either professionally or personally.

If you have found anything displayed incorrectly or have further suggestions on improving our effort, please do not hesitate to reach out at pharmainfonepal1@gmail.com !
We hope you find Pharma info Nepal a helpful site. Thanks !!!

Categories

  • B Pharmacy
  • Colleges
  • D Pharmacy
  • Downloads
  • License
  • Loksewa
  • M Pharmacy
  • Medicinal Chemistry
  • Notice
  • Nursing
  • Pharmacognosy
  • Pharmacology
  • Questions
  • Scholarship
  • Study Materials
  • Syllabus
  • Updates
  • Vacancy

DOWNLOADS

Pharmacy Book 

Pharmacy Act and Guidelines

About Pharma Info Nepal

About Admin

  • About
  • Privacy Policy
  • Terms Of Use
  • Contact

© 2021 Nabin's Blog

No Result
View All Result
  • Home
  • Loksewa
  • License
  • Questions
  • Vacancy
  • Downloads
  • Notice

© 2021 Nabin's Blog

error: